

# KEWAUNEE SCIENTIFIC CORP /DE/

## **FORM 8-K** (Current report filing)

Filed 06/19/19 for the Period Ending 06/18/19

Address	2700 W FRONT ST STATESVILLE, NC, 28677
Telephone	7048737202
CIK	0000055529
Symbol	KEQU
SIC Code	3821 - Laboratory Apparatus and Furniture
Industry	Business Support Supplies
Sector	Industrials
Fiscal Year	04/30

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**  
**Date of Report (Date of earliest event reported): June 18, 2019**

---

**Kewaunee Scientific Corporation**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**0-5286**  
(Commission  
File Number)

**38-0715562**  
(I.R.S. Employer  
Identification No.)

**2700 West Front Street**  
**Statesville, North Carolina**  
(Address of principal executive offices)

**28677**  
(Zip Code)

**Registrant's telephone number, including area code: 704-873-7202**

**N/A**  
(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$2.50 par value	KEQU	NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

---

---

**Item 2.02 Results of Operations and Financial Condition**

On June 18, 2019, Kewaunee Scientific Corporation issued a press release announcing its financial results for the fourth quarter and fiscal year ended April 30, 2019. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits:

**Exhibit No.**

99.1 [Press Release of Kewaunee Scientific Corporation dated June 18, 2019.](#)

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

---

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

(Registrant)  
Kewaunee Scientific Corporation

Date: June 19, 2019

**/s/ Thomas D. Hull III**

Thomas D. Hull III  
President  
Chief Executive Officer



**Kewaunee Scientific Reports  
Results for Fiscal Year and Fourth Quarter**

Exchange: NASDAQ (KEQU)

Contact: Thomas D. Hull III  
704/871-3290

STATESVILLE, N.C. June 18, 2019 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its fourth quarter and its fiscal year ended April 30, 2019.

**Full Year, Fiscal Year 2019 Results:**

- Sales of \$146,550,000, a decrease of 7.3% from the prior year.
- Pre-tax earnings of \$2,134,000, a decrease of 77.8% from the prior year.
- Net earnings of \$1,529,000, a decrease of 71.0% from the prior year.
- Diluted earnings per share of \$0.55, a decrease of 71.1% from the prior year.
- Order backlog of \$100,829,000 at April 30, 2019, a decrease of 13.3% from the prior year.

**Fourth Quarter, Fiscal Year 2019 Results:**

- Sales of \$34,748,000, a decrease of 21.9%, as compared to sales of \$44,508,000 in the prior year fourth quarter.
- Pre-tax loss of \$1,554,000 as compared to pre-tax income of \$2,640,000 in the prior year fourth quarter.
- Net loss of \$1,270,000 as compared to net income of \$1,556,000 in the prior year fourth quarter.
- Diluted loss per share of \$(0.46), as compared to diluted earnings per share of \$0.56 in the prior year fourth quarter. One-time non-operating costs related to management changes had an unfavorable impact of \$0.31 per share on earnings for the quarter.

Sales during fiscal year 2019 were \$146,550,000, a decrease of 7.3% from sales of \$158,050,000 in the prior year. Domestic sales for the fiscal year were \$116,586,000, an increase of 1.7% from sales of \$114,594,000 in the prior year. International sales for the fiscal year were \$29,964,000, a decrease of 31.0% from sales of \$43,456,000 in the prior year.

Pre-tax earnings for the fiscal year were \$2,134,000, a decrease of 77.8% compared to \$9,619,000 for the prior period. Net earnings decreased 71.0% for the fiscal year to \$1,529,000, or \$0.55 per diluted share, as compared to net earnings of \$5,281,000, or \$1.90 per diluted share, for the year ended April 30, 2018.

CORPORATE OFFICES • P. O. BOX 1842, STATESVILLE, NORTH CAROLINA 28687-1842 • 2700 WEST FRONT STREET, STATESVILLE, NORTH CAROLINA 28677-2927  
PHONE 704-873-7202 • FAX 704-873-1275



Pre-tax earnings were impacted by a significant decline in the Company's Domestic operating volumes during the second half of the fiscal year and higher raw material costs in steel and resin that were not able to be passed along to customers. International pre-tax earnings were impacted by the year-over-year decline in sales as well as the year-over-year decline in the exchange rate of the Indian rupee versus the US dollar. Finally, overall profitability was impacted by one-time non-operating costs related to management changes.

The Company's order backlog was \$101 million at April 30, 2019, compared to \$96 million at January 31, 2019, but lower than the \$116 million at April 30, 2018.

Unrestricted cash on hand at April 30, 2019 was \$10,647,000, as compared to \$9,716,000 at April 30, 2018. Working capital was \$32,624,000, as compared to \$36,775,000 at the end of the fourth quarter last year. Short-term debt and interest rate swaps were \$9.5 million at April 30, 2019, as compared to \$3.9 million at the end April 30, 2018, and long-term debt was \$1,413,000 at April 30, 2019 as compared to \$2,431,000 at the end of April 30, 2018. The Company's debt-to-equity ratio at April 30, 2019 was .23-to-1, as compared to .13-to-1 at April 30, 2018.

"Fiscal year 2019 proved to be a challenging year for Kewaunee," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "The second half of the year was especially demanding, as the Company was unable to convert the quotes necessary to achieve our desired operating levels.

"With a renewed commercial focus, we are beginning to see a reversal of booking trends from fiscal year 2019. We are working actively with our channel partners to improve our win rate and are encouraged by early results. Rebounding from fiscal year 2019 performance is of paramount importance, and I believe the pace of activity and investment in the marketplace is sufficient for Kewaunee to achieve this objective."

#### *About Kewaunee Scientific*

Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel, wood, and laminate casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin worksurfaces and sinks.

The Company's corporate headquarters are located in Statesville, North Carolina. Direct sales offices are located in the United States, India, Singapore, and China. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local and Asian markets. The Company's China headquarters and sales office are located in Shanghai, China. Kewaunee Scientific's website is located at <http://www.kewaunee.com>.

CORPORATE OFFICES • P. O. BOX 1842, STATESVILLE, NORTH CAROLINA 28687-1842 • 2700 WEST FRONT STREET, STATESVILLE, NORTH CAROLINA 28677-2927  
PHONE 704-873-7202 • FAX 704-873-1275



*This press release contains statements that the Company believes to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company’s future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “predict,” “believe” and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. All forward-looking statements are subject to important factors, risks, uncertainties and assumptions, including industry and economic conditions that could cause actual results to differ materially from those described in the forward-looking statements. Additional information concerning these factors is contained in the Company’s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise .*

**Kewaunee Scientific Corporation**  
**Condensed Consolidated Statements of Operations (Unaudited)**  
*(\$ and shares in thousands, except per share amounts)*

	Three months ended April 30,		Twelve months ended April 30,	
	2019	2018	2019	2018
Net sales	\$ 34,748	\$44,508	\$ 146,550	\$ 158,050
Cost of products sold	29,906	35,390	121,231	125,891
Gross profit	4,842	9,118	25,319	32,159
Operating expenses	6,176	5,880	23,207	22,240
Operating earnings (loss)	(1,334)	3,238	2,112	9,919
Other income (expense), net	(111)	(525)	389	(1)
Interest expense, net	(109)	(73)	(367)	(299)
Earnings (loss) before income taxes	(1,554)	2,640	2,134	9,619
Income tax expense (benefit)	(357)	1,027	446	4,161
Net earnings (loss)	(1,197)	1,613	1,688	5,458
Less: net earnings attributable to the noncontrolling interest	73	57	159	177
Net earnings (loss) attributable to Kewaunee Scientific Corporation	\$ (1,270)	\$ 1,556	\$ 1,529	\$ 5,281
Net earnings (loss) per share attributable to Kewaunee Scientific Corporation stockholders				
Basic	(\$ 0.46)	\$ 0.58	\$ 0.56	\$ 1.94
Diluted	(\$ 0.46)	\$ 0.56	\$ 0.55	\$ 1.90
Weighted average number of common shares outstanding				
Basic	2,746	2,728	2,742	2,720
Diluted	2,746	2,795	2,794	2,777

**Kewaunee Scientific Corporation**  
**Condensed Consolidated Balance Sheets**  
*(\$ in thousands)*

	April 30, 2019	April 30, 2018
<b>Assets</b>		
Cash and cash equivalents	\$10,647	\$ 9,716
Restricted cash	509	1,242
Receivables, less allowances	33,259	32,660
Inventories	17,206	18,549
Prepaid expenses and other current assets	3,736	2,224
Total Current Assets	65,357	64,391
Net property, plant and equipment	16,462	14,661
Other assets	5,404	6,031
Total Assets	\$87,223	\$85,083
<b>Liabilities and Stockholders' Equity</b>		
Short-term borrowings and interest rate swaps	\$ 9,513	\$ 3,885
Current portion of long-term debt and lease obligations	1,184	1,167
Accounts payable	15,190	14,754
Other current liabilities	6,846	7,810
Total Current Liabilities	32,733	27,616
Other non-current liabilities	6,787	9,275
Total Liabilities	39,520	36,891
Kewaunee Scientific Corporation equity	47,100	47,730
Noncontrolling interest	603	462
Total Stockholders' Equity	47,703	48,192
Total Liabilities and Stockholders' Equity	\$87,223	\$85,083